Business context and reporting period
The supplied filing is Eyenovia, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2020, filed August 14, 2020. This differs from the request metadata, which names Hyperion DeFi, Inc. Eyenovia is a clinical-stage ophthalmic biopharmaceutical company developing microdose therapies using its Optejet delivery system; it reported no product revenue.
Financial performance and position
| Metric | Q2 2020 / June 30, 2020 | Comparable period / prior year-end |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Net loss | $5.02 million for the quarter; $10.47 million for six months | $5.33 million and $11.27 million, respectively, in 2019 |
| Loss per share, basic and diluted | $0.25 for the quarter; $0.56 for six months | $0.44 and $0.94, respectively, in 2019 |
| Operating expenses | $5.02 million for the quarter; $10.49 million for six months | $5.38 million and $11.33 million, respectively, in 2019 |
| Cash and cash equivalents | $10.19 million | $14.15 million at December 31, 2019 |
| Working capital / stockholders’ equity | $8.2 million / $8.32 million | Not stated for the comparable date in the filing text |
| Debt | $729,245 total: $421,599 current and $307,646 non-current | No notes payable at December 31, 2019 |
For the six months ended June 30, operating cash use was $9.92 million versus $11.04 million in 2019; investing cash use was $132,243 versus none. Financing provided $6.08 million, mainly from the March private placement, PPP loan, and warrant exercises. No meaningful operating margin comparison applies because the company had no revenue.
Material changes versus prior comparable period
- Quarterly net loss narrowed by about $318,000 year over year; six-month net loss narrowed by about $799,000.
- Quarterly R&D expense fell 18% to $2.92 million, primarily due to reduced clinical and non-clinical activity amid COVID-19 restrictions. Six-month R&D fell 14% to $6.55 million.
- Quarterly G&A rose 16% to $2.10 million, largely reflecting business-development professional services; six-month G&A rose 5% to $3.94 million.
- Cash declined $3.97 million during the first half, compared with a $10.49 million decline in the first half of 2019. Common shares outstanding increased to 19.94 million from 17.10 million at year-end, principally reflecting the 2020 financing and warrant exercises.
Outlook, risks, and unusual items
- Management stated that substantial doubt exists about the company’s ability to continue as a going concern for at least one year after issuance of the financial statements. Continued operations depend on raising additional capital; absent financing, the company may need to reduce costs and curtail R&D.
- After quarter-end, Eyenovia received a $4.0 million upfront payment under an Arctic Vision license and approximately $1.3 million from warrant exercises. The license covers MicroPine and MicroLine in Greater China and South Korea and provides for up to $41.75 million in additional development and regulatory milestone payments, plus product supply and royalty economics. Payments to Senju apply under the amended license arrangements.
- Management reported that enrollment in the MicroPine Phase III CHAPERONE study had resumed after pandemic-related delays, and anticipated starting MicroLine Phase III VISION trials in the coming months, subject to COVID-19 impacts. The company said it remained on track to file a MicroStat NDA in 2020, also subject to pandemic impacts.
- The company had completed MicroStat Phase III trials and reported positive results. MicroProst and MicroTears development had been deferred while resources focused on MicroLine, MicroPine, and MicroStat.
- The $463,353 PPP loan bears 1% interest and may be eligible for forgiveness, but the filing gives no assurance that forgiveness will be obtained. The company also reported related-party consulting, lease, and contract engineering arrangements. No legal proceedings were reported.
- COVID-19 disrupted trial enrollment and operations and reduced certain R&D activity. The filing also notes that $9.94 million of cash exceeded FDIC insurance limits at June 30, 2020.
Most important facts for investors to verify
- Confirm the issuer: the supplied filing names Eyenovia, Inc., not Hyperion DeFi, Inc.
- Assess cash runway and financing needs, including the effect of the subsequent $4.0 million license payment and approximately $1.3 million warrant proceeds against ongoing operating cash use.
- Track clinical-trial timelines, COVID-19 effects, and the expected MicroStat NDA filing, which are forward-looking and not assured.
- Review the Arctic Vision milestone, royalty, supply, and Senju payment terms, including the conditions for receiving potential milestone payments.
- Monitor potential dilution from outstanding options and warrants; the filing reported 6.69 million potentially dilutive securities excluded from diluted EPS as anti-dilutive.